Erythema Dyschromicum Perstans Medication

  • Author: Robert A Schwartz, MD, MPH; Chief Editor: Dirk M Elston, MD   more...
 
Updated: May 22, 2012
 

Medication Summary

The goals of pharmacotherapy are to reduce morbidity and to prevent complications.

Next

Leprostatics

Class Summary

Have both antimicrobial properties and anti-inflammatory properties. They were originally developed to treat tuberculosis.

View full drug information

Clofazimine (Lamprene)

 

Lipophilic rhimophenazine dye with antimicrobial and anti-inflammatory properties originally developed to treat tuberculosis. Inhibits mycobacterial growth, binds preferentially to mycobacterial DNA. Has antimicrobial properties, but mechanism of action unknown.

Although its mechanism of action is unclear, it seems to exert its main effect upon neutrophils and monocytes in a variety of ways (eg, stimulating phagocytosis and release of lysosomal enzymes).

View full drug information

Dapsone (Avlosulfon)

 

Bactericidal and bacteriostatic against mycobacteria; mechanism of action is similar to that of sulfonamides, in which competitive antagonists of PABA prevent formation of folic acid, inhibiting bacterial growth

Previous
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

Robert A Schwartz, MD, MPH  Professor and Head, Dermatology, Professor of Pathology, Pediatrics, Medicine, and Preventive Medicine and Community Health, University of Medicine and Dentistry of New Jersey-New Jersey Medical School

Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, and Sigma Xi

Disclosure: Nothing to disclose.

Coauthor(s)

Santiago A Centurion, MD  Staff Physician, Department of Dermatology, New Jersey Medical School, University of Medicine and Dentistry of New Jersey

Santiago A Centurion, MD is a member of the following medical societies: American Academy of Dermatology, American Medical Association, and Sigma Xi

Disclosure: Nothing to disclose.

Specialty Editor Board

Shyam Verma  MBBS, DVD, FAAD, Clinical Associate Professor, Department of Dermatology, University of Virginia; Adjunct Associate Professor, Department of Dermatology, State University of New York at Stonybrook, Adjunct Associate Professor, Department of Dermatology, University of Pennsylvania

Shyam Verma is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Michael J Wells, MD  Associate Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine

Michael J Wells, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, and Texas Medical Association

Disclosure: Nothing to disclose.

Jeffrey P Callen, MD  Professor of Medicine (Dermatology), Chief, Division of Dermatology, University of Louisville School of Medicine

Jeffrey P Callen, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, and American College of Rheumatology

Disclosure: Amgen Honoraria Consulting; Celgene Honoraria Safety Monitoring Committee

Catherine M Quirk, MD  Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania

Catherine M Quirk, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD  Director, Ackerman Academy of Dermatopathology, New York

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

References

  1. Ramirez CO. Los cenicientos: Problema Clinica. Memoria del Primer Congresso Centroamericano de Dermatologica,. 1957;122-130.

  2. Convit J, Kerdel-Vegas F. Erythema dyschromicum perstans a hitherto undescribed skin disease. J Invest Dermatol. 1961;36:457-62.

  3. Berger RS, Hayes TJ, Dixon SL. Erythema dyschromicum perstans and lichen planus: are they related?. J Am Acad Dermatol. Aug 1989;21(2 Pt 2):438-42. [Medline].

  4. Kark EC, Litt JZ. Ashy dermatosis--a variant of lichen planus?. Cutis. Jun 1980;25(6):631-3. [Medline].

  5. Naidorf KF, Cohen SR. Erythema dyschromicum perstans and lichen planus. Arch Dermatol. Sep 1982;118(9):683-5. [Medline].

  6. Penagos H, Jimenez V, Fallas V, O'Malley M, Maibach HI. Chlorothalonil, a possible cause of erythema dyschromicum perstans (ashy dermatitis). Contact Dermatitis. Oct 1996;35(4):214-8. [Medline].

  7. Molinero J, Vilata JJ, Nagore E, Obon L, Grau C, Aliaga A. Ashy dermatosis in an HIV antibody-positive patient. Acta Derm Venereol. Jan-Feb 2000;80(1):78-9. [Medline].

  8. Nelson MR, Lawrence AG, Staughton RC, Gazzard BG. Erythema dyschromicum perstans in an HIV antibody-positive man. Br J Dermatol. Dec 1992;127(6):658-9. [Medline].

  9. Correa MC, Memije EV, Vargas-Alarcon G, et al. HLA-DR association with the genetic susceptibility to develop ashy dermatosis in Mexican Mestizo patients. J Am Acad Dermatol. Apr 2007;56(4):617-20. [Medline].

  10. Vega-Memije ME, Dominguez-Soto L. Ashy dermatosis. Int J Dermatol. Feb 2010;49(2):228-9. [Medline].

  11. Vazquez-Lopez F, Vidal AM, Zalaudek I. Dermoscopic subpatterns of ashy dermatosis related to lichen planus. Arch Dermatol. Jan 2010;146(1):110. [Medline].

  12. Carboni I, Costanzo A, Campione E, Paterno EJ, Chimenti S. [Ashy dermatosis: clinico-pathological associations in two cases]. Clin Ter. Sep-Oct 2008;159(5):321-3. [Medline].

  13. Silverberg NB, Herz J, Wagner A, Paller AS. Erythema dyschromicum perstans in prepubertal children. Pediatr Dermatol. Sep-Oct 2003;20(5):398-403. [Medline].

  14. Torrelo A, Zaballos P, Colmenero I, Mediero IG, de Prada I, Zambrano A. Erythema dyschromicum perstans in children: a report of 14 cases. J Eur Acad Dermatol Venereol. Jul 2005;19(4):422-6. [Medline].

  15. Zaynoun S, Rubeiz N, Kibbi AG. Ashy dermatoses--a critical review of the literature and a proposed simplified clinical classification. Int J Dermatol. Jun 2008;47(6):542-4. [Medline].

  16. Mizukawa Y, Shiohara T. Fixed drug eruption presenting as erythema dyschromicum perstans: a flare without taking any medications. Dermatology. 1998;197(4):383-5. [Medline].

  17. Volz A, Metze D, Bohm M, Bruckner-Tuderman L, Nashan D. Idiopathic eruptive macular pigmentation in a 7-year-old girl: case report and discussion of differences from erythema dyschromicum perstans. Br J Dermatol. Oct 2007;157(4):839-40. [Medline].

  18. Srivastava N, Solanki LS, Chand S, Garbyal RS, Singh S. Ashy dermatosis-like pigmentation due to ethambutol. Indian J Dermatol Venereol Leprol. May-Jun 2008;74(3):281-2. [Medline].

  19. Gaertner E, Elstein W. Lichen planus pigmentosus-inversus: case report and review of an unusual entity. Dermatol Online J. Feb 15 2012;18(2):11. [Medline].

  20. Vega ME, Waxtein L, Arenas R, Hojyo T, Dominguez-Soto L. Ashy dermatosis and lichen planus pigmentosus: a clinicopathologic study of 31 cases. Int J Dermatol. Feb 1992;31(2):90-4. [Medline].

  21. Oiso N, Tsuruta D, Imanishi H, Kobayashi H, Kawada A. Erythema Dyschromicum Perstans in a Japanese Child. Pediatr Dermatol. Nov 8 2011;[Medline].

  22. Arbiser JL, Moschella SL. Clofazimine: a review of its medical uses and mechanisms of action. J Am Acad Dermatol. Feb 1995;32(2 Pt 1):241-7. [Medline].

  23. Tlougan BE, Gonzalez ME, Mandal RV, Kundu RV, Skopicki D. Erythema dyschromicum perstans. Dermatol Online J. Nov 15 2010;16(11):17. [Medline].

  24. Muñoz C, Chang AL. A case of Cinderella: erythema dyschromicum perstans (ashy dermatosis or dermatosis cinecienta). Skinmed. Jan-Feb 2011;9(1):63-4. [Medline].

  25. Bahadir S, Cobanoglu U, Cimsit G, Yayli S, Alpay K. Erythema dyschromicum perstans: response to dapsone therapy. Int J Dermatol. Mar 2004;43(3):220-2. [Medline].

  26. Baranda L, Torres-Alvarez B, Cortes-Franco R, Moncada B, Portales-Perez DP, Gonzalez-Amaro R. Involvement of cell adhesion and activation molecules in the pathogenesis of erythema dyschromicum perstans (ashy dermatitis). The effect of clofazimine therapy. Arch Dermatol. Mar 1997;133(3):325-9. [Medline].

  27. Combemale P, Faisant M, Guennoc B, Dupin M, Heyraud JD. Erythema dyschromicum perstans: report of a new case and critical review of the literature. J Dermatol. Nov 1998;25(11):747-53. [Medline].

  28. Convit J, Piquero-Martin J, Perez RM. Erythema dyschromicum perstans. Int J Dermatol. Apr 1989;28(3):168-9. [Medline].

  29. Epps RE. Case reports: selected dermatoses in children of color. J Drugs Dermatol. Jan 2007;6(1):78-82. [Medline].

  30. Gellin GA, Hilger R. Erythema dyschromicum perstans (Ashy dermatosis). Arch Dermatol. 1974;110:963.

  31. Gougerot MH. Lichen atypiques ou invisibles pigmentogenes reveles par des pigmentations. Bull Soc Fr Dermatol Syphiligr. 1935;42:792-4.

  32. Gougerot MH. Lichen atypiques ou invisibles pigmentogenes. Bull Soc Fr Dermatol Syphiligr. 1935;42:894-8.

  33. Henderson CD, Tschen JA, Schaefer DG. Simultaneously active lesions of vitiligo and erythema dyschromicum perstans. Arch Dermatol. Aug 1988;124(8):1258-60. [Medline].

  34. Lambert WC, Schwartz RA, Hamilton GB. Erythema dyschromicum perstans. Cutis. Jan 1986;37(1):42-4. [Medline].

  35. Miyagawa S, Komatsu M, Okuchi T, Shirai T, Sakamoto K. Erythema dyschromicum perstans. Immunopathologic studies. J Am Acad Dermatol. May 1989;20(5 Pt 2):882-6. [Medline].

  36. Paradisi M, Mostaccioli S, Celano G, et al. [Erythema dischromicum perstans (ashy dermatosis). Report of two cases]. Pathologica. Sep-Oct 1993;85(1099):533-41. [Medline].

  37. Piquero-Martín J, Perez-Alfonzo R, Abrusci V, et al. Clinical trial with clofazimine for treating erythema dyschromicum perstans. Evaluation of cell-mediated immunity. Int J Dermatol. Apr 1989;28(3):198-200. [Medline].

  38. Ramirez C. The ashy dermatosis (erythema dyschromicum perstans): epidemiological study and report of 139 cases. Cutis. 1967;3:244-7.

  39. Ramirez O, Lopez Lino DG. [Current status of ashy dermatosis. Synonym--erythema dyschromicum perstans]. Med Cutan Ibero Lat Am. 1984;12(1):11-8. [Medline].

  40. Samos-Zielinksa J, Lancucki J. Chronic toxic erythemo-macular skin hyperpigmentation (erythema dyschromicum perstans. Przegl Dermatol. 1978;66:385-91.

  41. Schwartz RA. Erythema dyschromicum perstans: the continuing enigma of Cinderella or ashy dermatosis. Int J Dermatol. Mar 2004;43(3):230-2. [Medline].

  42. Sebbag N, Lacour JP. [Erythema dyschromicum perstans]. Ann Dermatol Venereol. Jan 2006;133(1):79-82. [Medline].

  43. Soter NA, Wand C, Freeman RG. Ultrastructural pathology of erythema dyschromicum perstans. J Invest Dermatol. Feb 1969;52(2):155-62. [Medline].

  44. Tschen JA, Tschen EA, McGavran MH. Erythema dyschromicum perstans. J Am Acad Dermatol. Apr 1980;2(4):295-302. [Medline].

  45. Zenorola P, Bisceglia M, Lomuto M. Ashy dermatosis associated with cobalt allergy. Contact Dermatitis. Jul 1994;31(1):53-4. [Medline].

 
Previous
Next
 
Ash-colored, partially confluent, macular lesions over the patient's back. Reprint with permission from Cutis 1986; 37: 42-44.
Close-up photograph shows ash-colored macular lesions and lack of an inflammatory border. Reprint with permission from Cutis 1986; 37: 42-44.
Photomicrograph of a lesion on the patient's back shows slight basilar vacuolar change, extensive pigment incontinence, dilatation of dermal lymphatics, and lack of inflammation (hematoxylin & eosin, original magnification X24.8). Reprint with permission from Cutis 1986; 37: 42-44.
Higher-power photograph shows slight vacuolar basilar change, marked dilatation of intradermal lymphatics, incontinence of melanin pigment, and lack of inflammation (hematoxylin & eosin, original magnification X238). Reprint with permission from Cutis 1986; 37: 42-44.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.